Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
DNTH Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
43.40%
DNTH Stock Analysis
DNTH
PE Ratio:
DNTH
PEG Ratio:
Not Available
DNTH
Forward EPS Growth (12 month):
0.00%
DNTH
PS Ratio:
2655.3
DNTH
PSG Ratio:
156
DNTH
Forward Revenue Growth (12 month):
17.00%
DNTH Articles
No data was found